Attovia Therapeutics Reports $450,000 Revenue and $20.7 Million Net Loss for Q2 2026

Attovia Therapeutics, Inc. reported its financial results for the second quarter of 2026, revealing a total revenue of $450,000, attributed entirely to collaboration revenue from its EndPath Agreement. This marks a significant increase from the previous year, as the company had no revenue during the same period in 2025. However, the company continues to face substantial operating losses, with a net loss of $20.7 million for the quarter, compared to a net loss of $14.4 million in the prior year, reflecting a 43% increase in losses.

Operating expenses for the second quarter of 2026 totaled $22.3 million, a 34% increase from $16.6 million in the same quarter of 2025. The rise in expenses was primarily driven by a 39% increase in research and development costs, which reached $18.9 million, largely due to heightened clinical, manufacturing, and preclinical services associated with its product candidates, including ATTO-1310 and ATTO-2306. General and administrative expenses also saw a modest increase of 9%, totaling $3.3 million, as the company expanded its workforce and incurred higher professional service costs in preparation for its transition to a public company.

As of June 30, 2026, Attovia reported total assets of $128.3 million, a decrease from $165.9 million at the end of 2025. The decline in assets was primarily due to a reduction in cash and cash equivalents, which fell to $32.8 million from $40.2 million. The company’s accumulated deficit increased to $150.4 million, reflecting ongoing investments in research and development without any product revenue to offset these costs. The company’s employee headcount has also grown, supporting its expanding clinical and operational activities.

Strategically, Attovia has made significant advancements in its product pipeline, with three candidates under development using its proprietary ATTOBODY platform. The company is currently conducting a Phase 1 clinical trial for ATTO-1310 and expects to initiate trials for ATTO-2306 and ATTO-1091 in the first half of 2027. Additionally, Attovia completed its initial public offering (IPO) on August 6, 2026, raising approximately $305.4 million in net proceeds, which is expected to provide sufficient capital to fund operations into 2030.

Looking ahead, Attovia anticipates continued investment in its research and development efforts, with plans to expand its product pipeline and build commercialization capabilities. The company acknowledges the inherent risks associated with drug development and the need for additional capital to support its operations. Management remains optimistic about the potential of its product candidates and the future growth of the company, contingent upon successful clinical outcomes and regulatory approvals.